玻玛西林

SRT2104 (GSK2245840)是一种选择性 SIRT1 活化剂，参与能量平衡的调节。Phase 2。 SRT2104 reduces p65/RelA acetylation levels in C2C12 cells. In male C57BL/6J mice, SRT2104 (100 mg/kg, p.o.) extends both mean and maximal lifespan of mice fed a standard diet, and enhances motor coordination, bone mineral density, and insulin sensitivity and decreased inflammation. Short-term SRT2104 treatment preserves bone and muscle mass in an experimental model of atrophy. In Male N171-82Q HD mice, SRT2104 (diet containing 0.5% SRT2104) effectively penetrates the blood-brain barrier, attenuates brain atrophy, improves motor function, and extends survival. SRT2104 (GSK2245840)是一种选择性 SIRT1 活化剂，参与能量平衡的调节。Phase 2。

Target	Value
SIRT1

SRT2104降低C2C12细胞中p65/RelA乙酰化水平。

在雄性C57BL/6J小鼠体内，SRT2104 (100 mg/kg, p.o.)延长标准饮食喂养大鼠的平均和最大寿命，增强运动协调性，骨密度，和胰岛素敏感性，并减少炎症。在萎缩的实验模型中，短期SRT2104治疗保存骨头和肌肉质量。在雄性N171-82Q HD小鼠体内，SRT2104 (包含0.5% SRT2104的饮食)有效穿透血脑屏障，减弱脑萎缩，改善运动功能，并延长存活时间。